
CervoMed Inc. (NASDAQ:CRVO – Free Report) – Analysts at HC Wainwright increased their FY2026 EPS estimates for shares of CervoMed in a report issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($2.25) per share for the year, up from their previous estimate of ($2.32). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($2.23) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.50) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.35) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.44) EPS and FY2027 earnings at ($1.62) EPS.
CervoMed (NASDAQ:CRVO – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09.
Read Our Latest Report on CervoMed
CervoMed Stock Performance
Shares of NASDAQ CRVO opened at $1.83 on Wednesday. The business has a 50-day moving average of $2.36 and a 200-day moving average of $3.31. CervoMed has a fifty-two week low of $1.27 and a fifty-two week high of $10.00.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in shares of CervoMed during the 1st quarter worth about $252,000. BlackRock Inc. acquired a new stake in CervoMed in the 2nd quarter valued at about $167,000. Citizens Financial Group Inc. RI acquired a new stake in CervoMed in the 2nd quarter valued at about $116,000. Byrne Asset Management LLC grew its holdings in CervoMed by 248.6% during the second quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock worth $159,000 after purchasing an additional 36,550 shares during the period. Finally, NFSG Corp grew its holdings in CervoMed by 283.3% during the third quarter. NFSG Corp now owns 11,500 shares of the company’s stock worth $34,000 after purchasing an additional 8,500 shares during the period. Institutional investors own 25.15% of the company’s stock.
About CervoMed
CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s lead investigational product is neflamapimod, an orally administered, brain-penetrant small-molecule inhibitor of p38 alpha, an enzyme believed to play a role in neuroinflammation and cognitive decline. CervoMed is primarily evaluating neflamapimod as a potential treatment for dementia with Lewy bodies, a progressive neurological disorder associated with cognitive impairment, fluctuations in attention, visual hallucinations and movement symptoms.
Featured Articles
- Five stocks we like better than CervoMed
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.
